Insider Brief
- The SandboxAQ-Deloitte partnership aims at combining strengths of both companies to provide new tools for biopharma and other sciences.
- Identifying most promising data in large amounts of published literature could improve decision-making as to what will work and what won’t.
- Collaboration could use Large Quantitative Model AI to speed-up new drug discoveries and lower costs.
SandboxAQ has announced an expanded partnership with Deloitte with accelerating the drug discovery process as one of their goals.
The expanded partnership, announced Monday, will combine SandboxAQ’s AI-driven simulation solutions, AQBioSim and AQChemSim, with Deloitte’s consulting capabilities to enhance product development in biopharma, energy, and other sectors. This collaboration seeks to help organizations use AI in areas where traditional Large Language Models (LLMs) fall short.
“SandboxAQ is excited to expand its long-standing strategic alliance with Deloitte, whose relationships with some of the world’s largest organizations will accelerate the adoption of our quantitative AI technologies,” said SandboxAQ Chief Operating Officer Andrew McLaughlin, in a press release. “AI simulation with Large Quantitative Models represents the next evolution of AI and will have a transformative impact on how organizations create value for their customers in ways that Large Language Models cannot.”
Large Quantitative Models (LQMs) differ from LLMs in that they focus on numerical simulation and predictive analytics rather than text generation. These models process vast amounts of structured data and can improve decision-making in scientific research, materials development, and drug discovery.
“Using LQMs in collaboration with Deloitte’s Atlas AI™ knowledge graph capabilities will allow SandboxAQ’s scientists to automatically extract new clinical hypotheses from literature, highlighting only those most likely to be correct,” the company noted in its press release.
Deloitte’s consulting teams will work alongside SandboxAQ to assist pharmaceutical and life sciences companies in data evaluation, exploratory data analysis, and AI model testing. This approach will help researchers identify viable drug candidates more efficiently, potentially reducing the time and cost required to bring new treatments to market.
“With this expansion of our alliance, we’re able to combine our extensive experience in life sciences, data, and research with SandboxAQ’s leadership in AI simulation and Large Quantitative Models,” said Aditya Kudumala, principal at Deloitte Consulting LLP. “Together, we aim to advance drug discovery and materials science for leading academic, commercial, and public sector entities.”
